IP Library Granted Patent US 9,994,641
Granted Patent B2
US 9,994,641 · App. 15/107,839 · Granted Jun 12, 2018

Anti-human transferrin receptor antibody that passes through blood-brain barrier

Inventors: Hiroyuki Sonoda (Hyogo, JP); Hideto Morimoto (Hyogo, JP); Yuri Koshimura (Hyogo, JP); Masafumi Kinoshita (Hyogo, JP); Haruna Takagi (Hyogo, JP); Yoshiko Yoshii (Hyogo, JP)
Assignee: JCR PHARMACEUTICALS CO., LTD.
C07K16/2881C12N9/16C12Y301/06013A61K38/00A61K2039/505C07K2317/21C07K2317/34C07K2317/622C07K2319/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,994,641
App. No.
15/107,839
Granted
Jun 12, 2018
Kind
B2
Abstract

Disclosed are a novel anti-human transferrin receptor antibody comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 5, 6 and 7 that can pass through the blood-brain barrier, a fusion protein comprising a protein necessary to be brought into function in the central nervous system and the antibody, and method of their production. The fusion protein comprises amino acid sequences of an anti-human transferrin receptor antibody that recognizes an amino acid sequence selected from the group consisting of SEQ ID NOs:1, 2, and 3, and of other protein that is bound thereto on the C-terminal side.

Claims (10)

1. A single-chain anti-human transferrin receptor antibody comprising an amino acid sequence selected from the group consisting of SEQ ID Nos: 4, 5, 6, and 7.

2. A DNA sequence encoding the antibody according to claim 1 .

3. A fusion protein comprising the antibody according to claim 1 and another protein bound thereto on the C-terminal side.

4. The fusion protein according to claim 3 wherein the another protein is bound to the C-terminal side of the antibody by a linker sequence consisting of 3-50 amino acids.

5. The fusion protein according to claim 3 , wherein said another protein is a lysosomal enzyme.

6. The fusion protein according to claim 5 , wherein the lysosomal enzyme is human iduronate 2-sulfatase.

7. A DNA sequence encoding the fusion protein according to claim 3 .

8. A mammalian expression vector comprising the DNA sequence according to claim 7 .

9. A mammalian cell transformed with the mammalian expression vector according to claim 8 .

10. The cell according to claim 9 , wherein the mammalian cell is a CHO cell.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 11, 2018
From: SONODA, HIROYUKI; MORIMOTO, HIDETO; KOSHIMURA, YURI; KINOSHITA, MASAFUMI; TAKAGI, HARUNA; YOSHII, YOSHIKO
To: JCR PHARMACEUTICALS CO., LTD.
Reel/Frame 045775/0646 →
Priority Claims (1)
JP P2013-266880 · Dec 25, 2013 · national
Continuity (1)
Related Publication 20160369001A1 · Dec 22, 2016